For example, 92.9% (13/14) of sporadic MMR-deficient GCs had MLH1 promoter methylation [236], whereas 0.0% (0/14) of MLH1-deficient LS CNS tumours and UCs had MLH1 promoter methylation [28]. The gene discussed is MLH1; the disease is central nervous system neoplasm.